Bayer’s pharmaceutical business may finally be entering a long-awaited growth cycle, but CEO Bill Anderson still can’t quite ...
The German giant has spent years being defined by Monsanto, Roundup and legal headaches. Now its drug business is finally ...
Tech Times on MSN
Bayer's Asundexian cuts recurrent stroke risk by 26% without added bleeding, wins China approval as FDA review advances
Bayer's asundexian reduces recurrent stroke risk 26% without added bleeding in OCEANIC-STROKE. Approved in China (Sunharbo®); under FDA Priority Review. AHA 2026 coverage.
The trial was a test for the continued viability of Roundup lawsuits after a Supreme Court ruling in Bayer's favor limited ...
By Roberto Samora SAO PAULO, Nov 4 (Reuters) - Bayer said on Wednesday it will launch 17 new biological products in Latin ...
A jury in St. Louis rejected claims by three women who blamed Bayer AG’s Roundup weedkiller for their cancers, bolstering the ...
The decision hands Bayer the first ever approval for a Factor XIa inhibitor, which aim to slow the activity of a protein that ...
Bayer Pharmaceuticals' COO Sebastian Guth discusses how important the use of AI is to the various aspects of the business. He ...
Bayer Crop Science at the 9th CIIE [Photo provided to chinadaily.com.cn] Eight China debuts and six CIIE debuts: advancing ...
The German group said the recovery in its pharma business allowed it to mitigate market pressures at its agricultural and consumer-health divisions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results